ProQR Therapeutics « Terug naar discussie overzicht

ProQR Therapeutics 2020

873 Posts, Pagina: « 1 2 3 4 5 6 ... 39 40 41 42 43 44 | Laatste

Omlaag ↓

Missolapola 17 maart 2021 12:48

ProQR to Present Results from Phase 1/2 Trial of QR-421a for Usher Syndrome

LEIDEN, Netherlands & CAMBRIDGE, Mass., March 17, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies for inherited retinal diseases (IRDs), today announced that Company management will present and discuss results from its Phase 1/2 Stellar trial of QR-421a in adults with Usher syndrome and non-syndromic retinitis pigmentosa (nsRP) on March 24, 2021. The data will be announced in a press release and management will host an investor conference call at 8:15 a.m. EDT the same day to discuss the results

Missolapola 24 maart 2021 12:49

ProQR Announces Positive Results from Clinical Trial of QR-421a in Usher Syndrome and Plans to Start Pivotal Trials

LEIDEN, Netherlands & CAMBRIDGE, Mass., March 24, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies for inherited retinal diseases (IRDs), today announced results from a planned analysis of its Phase 1/2 Stellar trial of QR-421a in adults with Usher syndrome and non-syndromic retinitis pigmentosa (nsRP) due to USH2A exon 13 mutations. In the trial, QR-421a demonstrated benefit on multiple measures of vision that moved in concordance, including visual acuity, visual fields, and optical coherence tomography (OCT) retinal imaging, after a single dose. QR-421a was observed to be well tolerated with no serious adverse events reported. Based on these findings, the Company plans to advance QR-421a to two parallel pivotal Phase 2/3 trials by year end 2021 – one in early-moderate patients, one in advanced patients.

Continue reading this press release

Or find all press releases here.

BPPP 24 maart 2021 14:25

voorbeurs +12%

Cum infamia 25 maart 2021 16:05

quote:
BPPP schreef op 24 maart 2021 14:25:
voorbeurs +12%

Tijdens beurs: +34,5%

Cum infamia 25 maart 2021 17:13

En zag zo even de + 63%, toch te vroeg mijn winst genomen maar "achteraf" kijkt men een koe in zijn kont is een gezegde....

BPPP 25 maart 2021 19:35

Als ik Yahoo Finance goed begrijp, is ieder aandeel PRQR vandaag (tot nu) gemiddeld zo'n 2,5 maal verhandeld. Dus het zal wel volatiel blijven de komende tijd.

Missolapola 25 maart 2021 21:37

Feest in de portefeuille vandaag!

TD_01 25 maart 2021 21:48

Verhandeld volume is niet normaal. Waarom gisteren dan niet gestegen na nieuwsbericht?

Tuut 25 maart 2021 23:39

Al nederlandse website tegen gekomen gefeliciteerd met stijging vandaag

Missolapola 30 maart 2021 22:22

ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares

LEIDEN, Netherlands & CAMBRIDGE, Mass., March 30, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for inherited retinal diseases (IRDs), today announced that it intends to offer and sell its ordinary shares in an underwritten public offering. All of the shares are being offered by ProQR. In addition, ProQR expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the offering amount in ordinary shares at the public offering price, less underwriting discounts and commissions. The proposed offering is subject to market conditions and other closing conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual terms of the offering.

Continue reading this press release

Or find all press releases here.

Missolapola 31 maart 2021 07:39

ProQR Prices $90 Million Underwritten Public Offering of Ordinary Shares

LEIDEN, Netherlands and CAMBRIDGE, Mass., March 30, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for inherited retinal diseases (IRDs), today announced the pricing of its previously announced underwritten public offering of 13,846,154 ordinary shares at a price to the public of $6.50 per share. All of the shares are being offered by ProQR. In addition, ProQR has granted the underwriters a 30-day option to purchase up to 2,076,923 additional ordinary shares at the public offering price, less underwriting discounts and commissions. Gross proceeds from the offering are expected to be approximately $90 million, assuming no exercise of the underwriters’ option to purchase additional shares.

Ron Kerstens 31 maart 2021 10:30

@Missolapola Je weet dat er ook een ProQR 2021 discussie is ?

Missolapola 31 maart 2021 13:19

quote:
Ron Kerstens schreef op 31 maart 2021 10:30:
@Missolapola Je weet dat er ook een ProQR 2021 discussie is ?

Oei, dat wist ik niet Ron.
Bedankt om er mij op te attenderen, ik ga er direct naar kijken

873 Posts, Pagina: « 1 2 3 4 5 6 ... 39 40 41 42 43 44 | Laatste

Aantal posts per pagina: 20 50 100 | Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum

Detail

Vertraagd	31 jan 2025 22:00
Koers	2,115
Verschil	-0,035 (-1,63%)
Hoog	2,210
Laag	2,040
Volume	260.607
Volume gemiddeld	494.320
Volume gisteren	197.263

ProQR Therapeutics NV nieuws

Meer ››